Ultragenyx Pharmaceutical (RARE) stock had a bullish inflow of $1.99 million worth of trades on uptick and an outflow of $1.52 million in downticks on Thursday. The total uptick to downtick ratio stood at 1.31. The net money flow into the stock was $0.47 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $0.1 million. $0.1 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. However, Ultragenyx Pharmaceutical (RARE) stock traded down $1.58 , and reached $49.27, a drop of -3.11% over the previous day. On a weekly basis, the stock is -7.65%, over the previous weeks close.
The stock has recorded a 20-day Moving Average of 5.78% and the 50-Day Moving Average is 17.65%. Shares have dropped -58.29% from its 1 Year high price. On Jul 20, 2015, the shares registered one year high at $137.05 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $59.89 and the 200 Day Moving Average price is recorded at $65.91.
Ultragenyx Pharmaceutical (NASDAQ:RARE): The stock opened at $52.19 on Thursday but the bulls could not build on the opening and the stock topped out at $52.92 for the day. The stock traded down to $48.33 during the day, due to lack of any buying support eventually closed down at $49.54 with a loss of -2.58% for the day. The stock had closed at $50.85 on the previous day. The total traded volume was 1,054,531 shares.
In an insider trading activity, The (Chief Medical Officer), of Ultragenyx Pharmaceutical Inc., Agarwal Sunil had unloaded 650 shares at $54.16 per share in a transaction on June 20, 2016. The total value of transaction was $35,204. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. Its products are KRN23 (UX023), rhGUS (UX003), rhPPCA (UX004), Triheptanoin (UX007) and SA-ER (UX001). KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. rhGUS is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7. rhPPCA is an enzyme replacement therapy for galactosialidosis. Triheptanoin is a medium odd-chain triglyceride of seven-carbon fatty acids. SA-ER is for the treatment of hereditary inclusion body myopathy (HIBM).